Although no studies are known in cancer but it is implicated in immunodeficiency disorders such as activated PI3Kδ syndrome/p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI) where it has been tested in phase II/III trials. This evidence concerns the gene PIK3CD and cancer.